Gilead Sciences, Inc. and Arcus Biosciences, Inc. have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into inflammation. Arcus will receive $35 million upfront and will initiate research programs against up to four targ...